XELJANZ / XELJANZ XR® (tofacitinib) Drug Interactions

(tofacitinib)

Prescribing Information

Health Professional Information

Drug Interactions

7 DRUG INTERACTIONS

Table 6 includes drugs with clinically important drug interactions when administered concomitantly with XELJANZ/XELJANZ XR/XELJANZ Oral Solution and instructions for preventing or managing them.

Table 6: Clinically Relevant Interactions Affecting XELJANZ/XELJANZ XR/XELJANZ Oral Solution When Coadministered with Other Drugs
Strong CP3A4 Inhibitors (e.g., ketoconazole)
Clinical Impact	Increased exposure to tofacitinib
Intervention	Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]
Moderate CYP3A4 Inhibitors Coadministered with Strong CYP2C19 Inhibitors (e.g., fluconazole)
Clinical Impact	Increased exposure to tofacitinib
Intervention	Dosage adjustment of XELJANZ/XELJANZ XR/XELJANZ Oral Solution is recommended [see Dosage and Administration (2), Clinical Pharmacology, Figure 3 (12.3)]
Strong CYP3A4 Inducers (e.g., rifampin)
Clinical Impact	Decreased exposure to tofacitinib and may result in loss of or reduced clinical response
Intervention	Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended [see Clinical Pharmacology, Figure 3 (12.3)]
Immunosuppressive Drugs (e.g., azathioprine, tacrolimus, cyclosporine)
Clinical Impact	Risk of added immunosuppression; coadministration with biologic DMARDs or potent immunosuppressants has not been studied in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, UC, or pcJIA.
Intervention	Coadministration with XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended [see Indications and Usage (1), Clinical Pharmacology, Figure 3 (12.3)]

Medication Guide

Download Consumer Medicine Information

Health Professional Information

Additional Resources

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.

Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.

Available 9AM-5PM ET Monday to Friday; excluding holidays.

Submit a medical question for a Pfizer medicine or a vaccine.

The submission will be reviewed during our standard business hours.

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.